MedTrace Logo

Adherence to Fluid Intake Recommendations in Kidney Stone Patients

NCT05329389 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2023-05-09

No results posted yet for this study

Summary

The cumulative risk of stone recurrence rate is up to 14% at 1 year, 35% at 5 years, and 52% at 10 years. Low urine volume caused by insufficient fluid consumption is one of the most crucial risk factors for kidney stone formation. According to the guidelines, a copious fluid intake to maintain a urine volume of at least 2.0 to 2.5 L/24 h is recommended for most kidney stone formers. Patients often find it difficult to follow the recommendations in fluid intake, which leads to stone recurrence. Therefore, there is a need to improve patient compliance and adherence to following the instructions on keeping water balance. For this purpose we developed a mixed educational program including two parts. The first is the mobile application called "StoneMD: Kidney Stones". The second is the "School for Patients" with kidney stones, which is responsible for the stone clinic effect.

Conditions

  • Urolithiasis

Interventions

DEVICE

StoneMD

StoneMD - is an app from App Store (for iOS) or Google Play (for Android).

BEHAVIORAL

Schools of Patients

The "Schools for Patients" with Urolithiasis is an online course for patients with urinary stone disease.

BEHAVIORAL

Standard recommendation

Only fluid balance recommendations given at the day of discharge.

Sponsors & Collaborators

  • Gadzhiev Nariman

    lead OTHER

Principal Investigators

  • Nariman Gadzhiev, PhD · Deputy Medical Director

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2024-04-04
Completion
2024-07-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329389 on ClinicalTrials.gov